International Projects


 

China

The electronic edition of World Journal of Gastroenterology is available at
http://www.wjgnet.com
This website provides you advanced and up-to-date basic researches in the
fields of gastroenterology and hepatology, especially on topics like
esophageal cancer, gastric cancer, liver cancer, colorectal cancer, viral
hepatitis.
Over 50% of the researches are original papers supported by the China
National Natural Science Foundation.
The journal has been indexed by IM, SCI, EM, CA, AJ, etc.
The JCR 2000 IF is rated 0.993 (according to JCR).
The JCR 2001 IF is rated 1.445 (according to JCR).
More information from:
Prof. Lian -Sheng Ma
President of the WJG Press
Editor-in-Chief
World Journal of Gastroenterology
P.O.Box 2345, Beijing 100023,China
Fax:+86-10-85381893
Email:wcjd@public.bta.net.cn
http://www.wjgnet.com

The First Sino-European Workshop on Immunogenetics and Pathogenesis of Gastric Cancer
Xi'an, China 26-28 April 2001

Participants of the workshop:
Europe
B. Appelmelk (Amsterdam, the Netherlands), H. Bazin and D. Latinne (Brussels, Belgium), J. Crabtree (Leeds, UK), B. Crusius (Amsterdam, the Netherlands), A. Lanas (Zaragoza, Spain), N. Muñoz (Lyon, France), D. Pantoflickova (Lausanne, Switzerland), A.S. Peña (Amsterdam, the Netherlands), S. Shivananda (Oegstgeest, the Netherlands), P. Sipponen (Espoo, Finland), J. Telford (Sienna, Italy) and L.J. van Doorn (Delft, the Netherlands).
China
W.Y. Chan (Hong Kong), D. Fan (Xi'an), D. Fang (Chongqing), J. Hu (Xi'an), P.J. Hu (Guangzhou), Y. Lu (Beijing), X. Ouyang (Chengdu), B. Pan (Xi'an), B.C.Y. Wong (Hong Kong), K. Wu (Xi'an), S. Xiao (Shanghai), Y. Yuan (Shenyang), J. Zhang (Guangzhou) and L. Zhang (Beijing).

European-Chinese research collaboration initiated at the First Sino-European Workshop on Immunogenetics and Pathogenesis of Gastric Cancer

 

A report from Leanne Fairley, Prous Science, Barcelona, Spain

Top level scientists from eight European countries and China gathered in the ancient Chinese capital of Xi'an on April 26-28 to discuss collaboration on a modern approach to gastric cancer prevention. Participants at the First Sino-European Workshop on Immunogenetics and Pathogenesis of Gastric Cancer presented their most up-to-date research results on topics ranging from epidemiology and immune mechanisms to Helicobacter pylori and vaccine development. Researchers then formed groups with their Chinese or European counterparts to plan future research endeavors which will benefit Chinese and European populations alike. After 3 years of organization between the Institute of Digestive Diseases of the Fourth Medical University in Xi'an, China and the Laboratory of Gastrointestinal Immunogenetics of the Free University Medical Center in Amsterdam the first workshop came into being under the joint sponsorship of the Commission of the European Union, National Natural Science Foundation of China and the Institute of Digestive Diseases, Xi'an, China. As gastric cancer is the most prevalent malignant tumor in China, the workshop was of special significance to the Chinese researchers and to the Chinese population in general. Leanne Fairley from Prous Science was in Xi'an to cover the proceedings and reinforce Prous Science's interest in the latest developments in Chinese research.
During the workshop, presentations on the epidemiology of gastric cancer showed that this disease is in fact common the world over: it is the second most common cancer next to lung cancer and about 1 million new cases were diagnosed in 2000. Three-quarters of the cases of gastric cancer occur in Asia, and approximately 80% of these cases are in China and Japan. Genetic factors and environmental factors such as diet and H. pylori infection play a role in gastric carcinogenesis.
As a recognized cause of gastric cancer, H. pylori was the subject of various presentations ranging from immunological studies, molecular analysis of strains and pathogenesis to vaccine development. Specific areas of discussion included bacterial-epithelial interactions in H. pylori infection, epidemiology in China, global distribution of vacA and cagA genotypes, new evidence for host factors, nonsteroidal antiinflammatory drugs and H. pylori as independent risk factor for gastric cancer, new diagnostic techniques for H. pylori using serum levels of pepsinogen I, and autoimmune processes in corpus atrophy.
Vaccine development using a variety of strategies against H. pylori was the subject of an entire session of talks. Oral immunization with urease with Escherichia coli heat labile enterotoxin was shown to be safe and immunogenic in humans as a mucosal adjuvant. Results of a study using attenuated Salmonella typhimurium as a vehicle for DNA-mediated immunization in mice were also presented. A final presentation discussed an ongoing trial comparing strain variability in the vacA and cagA gene sequences and disease expression between H. pylori infection in Europe and China.

Researchers also discussed the role of IL1 family and tumor necrosis factor gene polymorphisms in gastric pathology and various immune mechanisms involved in gastric cancer such as down-regulation of NFkB, IL1, IL1RA, cyclooxygenase signaling, and identification of MGAg antibodies.


An interactive discussion followed each presentation and ideas and suggestions were provided. According to specialty, the presenters were then assigned to groups of four or five to make plans for joint research projects. A number of international and Chinese observers were present, including representatives from the European Commission, the World Health Organization and the Chinese National Center for Biotechnology Development, and offered input on the financial feasibility of such projects. With this in mind, plans to continue the scientific and cultural collaboration at a Second Sino-European Workshop on Immunogenetics and Pathogenesis of Gastric Cancer in Finland are underway.

The proceedings of the First Sino-European Workshop on Immunogenetics and Pathogenesis of Gastric Cancer will be published in Prous Science's Methods and Findings and also on the TTMed channel.



Immunogenetic Studies in Inflammatory Bowel Disease

Participants

1. Laboratory of Gastrointestinal Immunogenetics, Medical Faculty Vrije Universiteit, Amsterdam, The Netherlands (Professor A.S. Peña, Head of the Laboratory of Gastrointestinal Immunogenetics of the Free University Amsterdam; Dr. S. Shivananda, Scientific Advisor & Honorary Professor of Medicine, Hubei Medical University Wuhan)

2. Department of Gastroenterology, Second Affiliated Hospital, Hubei Medical University, PR of China (Dr. Bing Xia, Department of Gastroenterology, Second Affiliated Hospital of Hubei Medical University, Wuhan; Prof. Changsheng Deng, Head of the Department of Gastroenterology, Second Affiliated Hospital of Hubei Medical University, Wuhan)
 


 

Introduction

          Inflammatory bowel disease (IBD) is a chronic, debilitating disease of the gut. It is a life-long disease and has no cure. Its etiology is unknown. Genetic as well as environmental factors are known to play an important role in the pathogenesis of this disease. So far, most studies in this field have been done in the laboratories and the populations of America, Europe and Israel. They have made an important contribution to our knowledge about disease causation. But the results remain inconclusive.

          Understanding the genetic determinants of disease susceptibility in the Chinese population and a study of the influence of putative environmental factors such as smoking, the diet, and viral infection in the rapidly changing Chinese society may make an important contribution to the advancement of knowledge on the aetiology of this disease. This project provides a unique opportunity to conduct these studies in a population with a different genetic background and a different environment.

          Since a disturbed immune response is involved in the development of this disease the Laboratory of Gastrointestinal Immunogenetics of the Vrije Universiteit Amsterdam is focused on immunogenetic studies for further understanding of the pathogenesis of this disease. Our plan is to set up a laboratory of immunogenetics and genetic epidemiology at the Second Affiliated Hospital of the Hubei Medical University in Wuhan that will enable the Chinese counterpart to collaborate with us in Amsterdam.

Aims

1. To perform immunogenetic studies in Chinese patients with IBD (to investigate cytokine gene polymorphisms)
2. To investigate the production of cytokines and the autoantibody peri-nuclear anti-neutrophil cytoplasmic antibodies (pANCA) in patients with IBD in China

Subjects

- Chinese patients with ulcerative colitis and Crohn's disease
- Chinese patients with infectious colitis, intestinal tuberculosis and other intestinal diseases
- Unrelated healthy controls from the Chinese population from Hubei province

Methods

Goals

1. A study of systemic and mucosal cytokine production in Chinese patients with IBD and controls will be conducted in order to improve our understanding of the factors influencing the disturbed immune response in IBD.
2. To establish whether a genetic background determines this immune response cytokine gene polymorphisms will be related to the production of these cytokines in case-control studies of Chinese IBD patients.
3. A high percentage of pANCA positive patients with ulcerative colitis has been observed in Western countries. The frequency of pANCA in Chinese patients with ulcerative colitis and other colitides and healthy controls will be established.


Report of a visit to the Peoples Republic of China

From left to right :
Prof General Su Bo, President of the 4th Military Medical University Xi'an
J.B.A. Crusius BSci Biol VU Amsterdam
Hon Prof. S. Shivananda Wuhan and VU Hon Investigator
Dr. H. van der Erve, DOS, VU
Prof. Xia Bing Wuhan

From 31-07-1999 until 08-08-1999 a delegation from the Vrije Universiteit Amsterdam (VUA), consisting of Dr. S. Shivananda, Drs. J.B.A. Crusius, and Dr. H.J. van der Erve visited the Fourth Military Medical University (FMMU) in Xi'an also on behalf of Prof. A.S. Peña from the Laboratory of Immunogenetics of the Faculty of Medicine of the VUA.

Aim of the visit was to discuss with the partners of the Institute of Digestive Disease the possibilities for research cooperation in the field of Immunogenetics and Epidemiology of Helicobacter pylori (H. pylori), peptic ulcer & especially in gastric cancer and to investigate the possibility of a wider agreement of interest to both Institutes.

We met the President of the FMMU, Professor Su Bo. Information was exchanged about both universities and we made a tour through the new building of the university. We visited the research labs, teaching rooms, library, and computer instruction halls. The premises and facilities of FMMU were quite impressive. The university is expanding the use of computers in education and is quite interested in receiving a computer assisted learning Programme from the Medical Faculty of the VUA. Van der Erve will send a copy of the existing Programme as attached file by E-mail.

Professor Su Bo is very interested to have an agreement with the VUA in order to be able to start cooperation in more fields that might be interesting for both universities. If cooperation can come off the ground it will mainly play in a broad field of medical oriented topics. Dr. van der Erve promised to discuss in Amsterdam the possibilities for an agreement between both universities.

In a preparatory meeting with Prof. Fan Daiming and Prof. Pan Bo-Rong we discussed what route should be followed to try to formulate a good research proposal and how and where to apply for funding. We concluded that first a workshop should be held and that at the end of that workshop, based on the presentation of the state-of-the art of the topics of interest and the discussions, a research proposal will be formulated. For the workshop the VUA will approach the European Commission for funding.

During a meeting with a larger group of persons, Prof. Pan Bo-Rong, Prof. Fan Daiming, Prof. Bing Xia from Wuhan (who already has an established collaboration with the Laboratory of Immunogenetics of the VUA and is a PhD graduate from the VUA), Prof. Kaichun Wu, Dr. Jie Liu, we discussed the content and the organization of what will be called the First Sino-European Workshop on Immunogenetics and Epidemiology of Helicobacter pylori, Peptic Ulcer & Gastric Cancer. It will be hopefully be held in Xi'an in September 2000.

At the end of the meeting a Letter of Agreement was signed. Further we discussed a draft proposal for the workshop. VUA will prepare a new version of the proposal and will send it to Xi'an for consultation before it will be used for a grant application to the European Commission INCO-DEV Programme.


From left to right :
Chinese Clinical Investigator
Hon Prof. S. Shivananda
Prof. Fan Daiming,
Prof. General Su Bo
Dr, H. van Erve
Prof. Bing Xia


 

Report of the visit of Elly Klinkenberg-Knol to San José, Costa Rica
11- 15 February 2001


foto: sidney vervuurt, avc vu

Introduction
Since many years there is a co-operation between the University of Costa Rica, San José, and the Vrije Universiteit Medical Center.
The main representatives in Costa Rica are Dr. Rafaela Sierra, epidemiologist from the "Institute de investigaciones en Salud (INISA)" and Dr. Edgar Izquierdo, gastroenterologist, University Hospital Calderón Guardia, San José.
The main representative in the Netherlands is prof. dr. Salvador Peña, gastroenterologist and head of the immunogenetic laboratory of the Vrije Universiteit Medical Center.
The main common interest of this international contact is the relation between Helicobacter pylori infection and gastric carcinoma.

Gastric Cancer
Cancer of the distal stomach is strongly associated with Helicobacter pylori colonization. This bacterium causes chronic active inflammation of the gastric mucosa in most of colonized subjects. In a considerable number of them, this will eventually lead to a loss of gastric glands, and thus the establishment of atrophic gastritis, which is associated with the development of intestinal metaplasia and dysplasia. The presence of these consecutive disorders leads to a 5-90 fold increased risk for cancer of the distal stomach. This sequence explains the increased risk for gastric cancer in Hp infected subjects, as has been shown in various cross-sectional and longitudinal studies. Factors that influence the risks for atrophy and cancer in the presence of infection may be related to the time that infection occurred and to characteristics of the bacterial strain and the host.
Distal stomach cancer is the most frequently occurring malignant tumor in Costa Rica and the mortality rate from this tumor is the highest for any type of cancer in the world.

Proposal
It would be very challenging to study in Costa Rica the causal factors for gastric carcinoma because of the high frequency of gastric cancer as well as Hp infection. There are intracountry, regional differences in the incidence of gastric cancer, even in this small country (comparable in size with the Netherlands) of 3.2 million inhabitants, although the prevalence of Hp infection does not differ significantly. Therefore, it is very interesting to study other factors, like characteristics of the bacterial strains and the host. Particularly genetic factors and intraindividual differences in immunologic response to the Hp infection are worthwhile to study. Why will one person develop only an acute gastritis and the other chronic atrophy and carcinoma?

Available facilities in Costa Rica
In San Jose, Costa Rica, Rafaela Sierra, has collected serum and gastric biopsies from 502 Hp positive patients, who were referred for upper GI endoscopy. The protocol includes:
An epidemiologic questionaire, endoscopy with 2 antrum and 2 corpus biopsies for pathology and Hp determination, and serology for gastrin and pepsinogen levels as well as genetic and immunologic study material.

Dutch contribution
Our, Dutch, share would be to perform the genetic and immunological studies from the Costa Rica material and compare this with material from the Netherlands.
At the Vrije Universiteit Medical Center we have at our disposal gastric biopsies from 365 reflux patients, treated with omeprazole for up to 11 years. We know that 40% is Hp positive and also we know the degree of atrophic gastritis in these patients.
It would be very interesting to study the possible genetic and immunological factors, leading to atrophy and also look and the differences in the large group from a "third world"country, like Costa Rica.

Visit Cosa Rica
I visited Costa Rica for scientific reasons from 11-16 February 2001. In this period I visited three GI departments of University Teaching Hospitals: the Hospital Calderón Guardia, the Hospital Mexico and a private hospital: Hospital Bíblica. Also I visited the private practice of a GI surgeon originally from Japan and trained in Japan: Dr Wong. In Liberia, a regional capital in the north of Costa Rica I visited the GI department of the local regional hospital.
I was impressed with the scientific level of the doctors: within their financial limitations the standards of investigations and treatment were quite comparable with our situation.
Particularly the private endoscopic unit of Dr Wong was impressing. In my opinion this unit would be very suitable for performing studies in GI patients, particularly due to the outstanding data base capacities.

Next, I visited Dr Rafaela Sierra at the INISA institute and we discussed the possibilities for further cooperation between our universities.
Three conferences were scheduled: two in San Jose and one in Liberia. The subjects of the lectures were: Gastro-oesophageal reflux disease; long-term efficacy and safety of omeprazole; Hp infection and gastric cancer, and Hp causes accelerated gastric atrophy in users of PPI's.
From the discussions after the lectures I have learned that reflux disease is not a common encountered problem in Costa Rica. The main interest was the relation between Hp and gastric cancer.

Brief conclusion
I would recommend a further cooperation between Costa Rica, particularly the INISA institute, and the GI department of our university to study the causal factors for the development of gastric atrophy and gastric cancer, particularly in the field of genetics and immunology.

Amsterdam, March 2001

 

 

 


 

Hungary

Andrea Nemetz
Ágota Kovács

The Regulation of Key Inflammatory Mediators in Inflammatory Bowel Disease, in collaboration with A. Nemetz MD (photo) of the Semmelweiss University in Budapest (Hungary), and T. Molnár MD PhD of the Szeged University in Budapest.

References :

1. Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999;49(6):527-31.
 

2. Nemetz A, Kope A, Molnar T, et al. Significant differences in the interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in a Hungarian population with inflammatory bowel disease. Scand J Gastroenterol 1999;34(2):175-9.
 

3. Andrea Nemetz and Amado Salvador Pena, On the genetic contribution of osteoporosis and osteoporotic fractures Letter for Pekka Kannus, Mika Palvanen, Jaakko Kaprio, Jari Parkkari, and Markku Koskenvuo eBMJ, 23 Dec 1999; 319; 1334-1337. Electronic letters 1999 http://www.bmj.com/cgi/eletters/319/7221/1334#EL2

 

Ágota Kovács MD, PhD is a gastroenterologist of the Péterfy Hospital, in Budapest.

She is Director of the IBD outpatient clinic in Budapest.

She was secretary and founding member (1993) of the Hungarian Crohn Society of Hungary and in 1994 founding member of Hungarian Crohn Colitis Patients Association.

Dr. Kovács studied at the Budapest University and is specialist in Internal Medicine since 1966. She registered in 1988 as specialist in Gastroenterology. In 1961 studied at the Postgraduate School of Med. Dept. of Gastroenterology, specializing in IBD. In 1966 was at the Semmelweis Univ. Med. Clin. of Int. Med. assistant prof. In 1977 Univ. of Lund, Dept. of Tumorimmunology, research : development of of experimental colitis model in rats, six months 1978 obtained her PhD degree with the thesis on "Etiopathogenesis of ulcerative colitis"

Publications
In 1984 in Balassa Hosp. Budapest, Dept. Gastroenterology, head of dept.
1986 Inflammatory Bowel Disease , monography , Medicina Publ.
(second edition in progress )
1985 and 1986 two monographies on IBD in Hungarian, one them awarded with " Nivo " award of the Hungarian Medical Publisher 1988 What you need to know about IBD, Medicina Publublications.
Fent J, Balazs L, Buzas G, Erasmus LP, Holzl R, Kovacs A, Weisz J, Adam G. Colonic sensitivity in irritable bowel syndrome and normal subjects according to their hemispheric preference and cognitive style. Integr Physiol Behav Sci 1999;34(1):54-62.
Nemetz A, Nosti-Escanilla MP, Molnar T, Kope A, Kovacs A, Feher J, Tulassay Z, Nagy F, Garcia-Gonzalez MA, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999;49(6):527-31.
Kovacs A. [Intracutaneous skin test in inflammatory colonic diseases using Kunin antigen]. Orv Hetil 1981;122(32):1955-6.
Kovacs A, Magyar I. [Functional colonic disease]. Z Gesamte Inn Med 1973;28(7):199-203.
Kovacs A, Magyar I. [Functional colonopathy. The irritable colon syndrome]. Orv Hetil 1972;113(34):2032-5.

 

 

 

 

 


 

Spain - Zaragoza

Ulcus Pepticum, in collaboration with the Hospital Universitario de Zaragoza (Spain), Dr. A. Lanas.

Publications 2000-1998

1. Inarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 2000;35(3):242-6.

2. Arroyo MT, Lanas A, Sainz R. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine. Eur J Gastroenterol Hepatol 2000;12(3):313-8.

3. Lanas A, Remacha B, Sainz R, Hirschowitz BI. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol 2000;95(2):513-9.

4. Lanas A. NSAID use and abuse in gastroenterology: refractory peptic ulcers. Acta Gastroenterol Belg 1999;62(4):418-20.

5. Santolaria S, Lanas A, Benito R, Perez-Aisa M, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13(11):1511-8.

6. Lorente S, Lanas A, Aznar C, Jimenez E, Lozano R. [Recurrent digestive hemorrhage as a complication of an intraduodenal diverticulum]. Gastroenterol Hepatol 1999;22(6):282-5.

7. Lanas A. Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding. Ital J Gastroenterol Hepatol 1999;31(Suppl 1):S37-42.

8. Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999;11(4):375-81.

9. Jimenez P, Lanas A, Piazuelo E, Esteva F. Effects of extracellular pH on restitution and proliferation of rabbit oesophageal epithelial cells. Aliment Pharmacol Ther 1999;13(4):545-52.

10. Lanas A, Royo Y, Ortego J, Molina M, Sainz R. Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology 1999;116(1):97-107.

11. Sopena F, Lanas A, Sainz R. Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatory drug use. J Clin Gastroenterol 1998;27(4):316-20.

12. Jimenez P, Lanas A, Piazuelo E, Esteva F. Effect of growth factors and prostaglandin E2 on restitution and proliferation of rabbit esophageal epithelial cells. Dig Dis Sci 1998;43(10):2309-16.

13. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention [see comments] [published erratum appears in Lancet 1998 Nov 14;352(9140):1634]. Lancet 1998;352(9133):1016-21.

14. Lanas A, Bajador E, Serrano P, Arroyo M, Fuentes J, Santolaria S. Effects of nitrate and prophylactic aspirin on upper gastrointestinal bleeding: a retrospective case-control study. J Int Med Res 1998;26(3):120-8.

15. Piazuelo E, Lanas A, Jimenez P, Garcia-Gonzalez A, Esteva F. In vitro wound repair by human gastric fibroblasts: implications for ulcer healing. Dig Dis Sci 1998;43(6):1230-40.

16. Hirschowitz BI, Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998;114(5):883-92.

17. Lanas Arbeloa A, Serrano Aullo MT. [Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?]. Gastroenterol Hepatol 1998;21 Suppl 1:20-4.

18. Lanas A, Garcia-Gonzalez A, Esteva F, Piazuelo E, Jimenez P, Morandeira JR. Collagen secretion by human gastric and skin fibroblasts: implications for ulcer healing. Eur Surg Res 1998;30(1):48-54.
 

 




Spain - Madrid

IBD Unit 2003-2005

From Left to right: Carlos Taxonera, Sonia Izquierdo, Julio García Paredes, Professor Manuel Díaz-Rubio, Dulce Maria Cruz, Juan Luis Mendoza and Cristina Alba.

 

 

International IBD Unit 2001-2002

Hospital Clínico Universitario San Carlos (HCSC) , Madrid, Spain
Department of Digestive Diseases (head: Prof. M Díaz-Rubio)


Dr. J. García-Paredes, Dr M. Cruz-Santamaria, Dr. Juan Luis Mendoza

Inflammatory Bowel Disease (IBD) VUmc and HCSC started with then collaboration between the Laboratory of Immunogenetics and Department of Digestive diseases (HCSC) 1999.
Dr. J. García Paredes, Dr. G. López-Nava Breviere from the Department of Digestive Diseases, Hospital Clínico Universitario San Carlos (head: Prof. M Díaz-Rubio) and Dr. E. Gómez de la Concha, Department of Immunology HCSC.

Dr. Gontrand López de Nava Breviere and Dr. J. García-Paredes

J. García-Paredes MD, PhD. Associate Professor and Consultant;
E-mail: jgparedes@bitmailer.net


Mrs. Alicia Aparicio
Secretary

 

Recent publications:

  1. Fernandez-Arquero M, Lopez-Nava G, Garcia Paredes J, Martinez A, De la Concha EG, Figueredo MA, et al. Pancolitis and genetic markers in the Spanish population. Rev Esp Enferm Dig 1999;91:269-276.
  2. de la Concha EG, Fernandez-Arquero M, Martinez A, Vigil P, Vidal F, Lopez-Nava G, et al. Amino acid polymorphism at residue 71 in HLA-DR beta chain plays a critical role in susceptibility to ulcerative colitis. Dig Dis Sci 1999;44:2324-2329.
  3. Fernandez Arquero M, Lopez Nava G, De la Concha EG, Figueredo MA, Santa Cruz S, Dumitru CG, et al. HLA-DR2 gene and Spanish patients with ulcerative colitis. Rev Esp Enferm Dig 1998;90:243-249.
  4. Garcia Paredes J. [Tobacco and chronic inflammatory bowel disease (Editorial; comment)]. Rev Esp Enferm Dig 1998;90:829-32.
  5. Sevilla Mantilla MC, Ruiz de Leon A, Perez de la Serna J, Taxonera C, Garcia Paredes J, Diaz Rubio M. Manometry and 24-hour ambulatory pH monitoring at two levels of the esophagus in patients with and without esophagitis [see comments]. Rev Esp Enferm Dig 1998;90:145-54.
  6. De La Concha EG, Fernandez-Arquero M, Santa-Cruz S, Lopez-Nava G, Figueredo MA, Diaz-Rubio M, et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC). Clin Exp Immunol 1997;108:392-395.
  7. Mendoza Hernandez JL, Garcia Paredes J, Larrubia Marfil JR, Casimiro Peytavi C, Diaz-Rubio M. [Diagnosis of Gilbert's syndrome: current status of the fasting test. Review of the literature]. An Med Interna 1997;14:57-61.